Introduction
For cancer treatment, immunotherapy has been regarded as a rising therapeutic approach followed the traditional treatments, such as surgery, chemotherapy, and radiotherapy. [1] Mounting evidences in recent years have shown that the efficient immune response is the decisive factor to inhibit tumor growth. [2] To achieve this goal, it requires sufficient propagation of antigenic information. Tumor antigens are often processed by antigen presenting cells (APCs), and presented to naïve T cells to activate both CD8 + and CD4 + T cells. [3] The participation of the immune system makes it possible to amplify and propagate antigenic information and subsequently induce antigen specific immune response. [2] However, it will also activate the negative feedback mechanisms, which directly contributes to the immune evasion of tumor. [4] Therefore, the new treatment modality of cancer immunotherapy is required to potentially motivate cytotoxic T lymphocytes (CTLs) and helper T cells, and specifically overcome negative feedback developed by tumor, simultaneously.
One form of immunotherapy in cancer treatment is vaccination. During these years research, it has been developed into several categories, such as subunit vaccine and cellular vaccine. [5] Compared with conventional subunit vaccine that directly stimulates the immune system in vivo, cellular vaccine usually manipulates vaccination process ex vivo, e.g., dendritic cell (DC)-based vaccines. [6, 7] Promising experimental data have indicated that DC-based vaccines can sufficiently generate primed DCs. [8] [9] [10] [11] However, some challenges still remained with these primed DCs, including the poor migration efficiency of primed DCs to lymph node (LN), the labor intensive productive process, and the burdensome medical expenditure. [12] To overcome these drawbacks confronted with DC-based vaccines, it needs to specifically configure an in vivo network between vaccine and DCs. [13] Nanotechnology can fulfill this requirement. The prosperous development in engineering materials makes it possible for nanovaccine to precisely manipulate immunization in vivo. By carefully selecting materials and preparation procedures, nanovaccine can specifically deliver antigens to DCs and induce robust antitumor immunity. [14] [15] [16] [17] In the efforts to exploit the potential of cancer immunotherapy, immune resistance is an inevitable topic and needs to be tackled cautiously. Programmed death 1 ligand (PD-L1) is an important immune checkpoint molecular expressed on tumor cells. It can interact with programmed cell death receptor 1 (PD-1) expressed on T cells to activate the PD-1/PD-L1pathway, an immune checkpoint signal pathway, which acts as one of the main factor in suppressing antitumor function of T cells. [4, 18] Immune checkpoint therapy is an appropriate choice to unleash the negative feedback and bring T cell back to life. [19] [20] [21] [22] [23] According to the result from Chang et al., [24] D-peptide antagonist ( D PPA-1), a novel immune checkpoint antagonist, has the similar function with anti-PD-L1 antibody. It can efficiently block the PD-1/PD-L1 pathway with lower cost and more safety.
In this work, melanoma cells (B16F10) derived tumor lysate (TLS) was used as the resource of tumor-associated antigens (TAAs), which can provide all relevant TAAs due to the abundant and convenient antigen resources. [25] [26] [27] [28] TLS can be presented by MHC class I molecules to augment broader CD8 + T-cell immune response [29] and be loaded on MHC class II molecules to stimulate potential CD4 + T cells. [27] Different from other tumor antigens, it was identified that antigens derived from melanoma can be specifically recognized by CD4 + T cells, [30] which could make TLS more suitable to eradicate B16F10 melanoma cells. Considering the water-solubility and active site of TLS, we introduced lipid-enveloped zinc phosphate hybrid nanoparticles (LZnP NPs) to enhance the stability and immunogenicity of antigens. In our previous work, ZnP NPs have shown the superiority in encapsulation of hydrophilic antigens with adjuvant-like feature. After modified with phospholipid bilayer, LZnP NPs were capable to entrap lipid-like adjuvant and efficiently drain to LNs from the injection site with a long-term accumulation. [31] Thus, LZnP NPs were further employed to load TLS and a TLR4 agonist, monophosphoryl lipid A (MPLA) to motivate the immune system to fight against melanoma. At the same time, immune checkpoint antagonist, D PPA-1, was involved to synergistically work with nanovaccine via disrupting negative feedback on T cells (Figure 1) . To identify the immunogenicity of vaccination therapy, we evaluated the immune response induced by the nanovaccine both in vitro and in vivo. And the therapeutic efficiency of combination therapy based on LZnP nanovaccine and D PPA-1 was evaluated through therapeutic and prophylactic protocols against melanoma. Our results provided promising support to combine nanovaccine with immune checkpoint antagonist in cancer treatment.
Results and Discussion

Preparation and Characterization of LZnP Nanovaccine
To obtain TLS-loaded LZnP nanovaccine, we first prepared B16F10 derived TLS as the route showed in Figure 2a . The synthesis of nanovaccine was accomplished by adding TLS to the Zn phase and interacting with P phase to form regular inorganic nanoparticles (Figure 2b ). In order to provide nanoparticles with good dispersivity and better biocompatibility in physical condition, we employed lipids composition to further modify nanoparticles. Here cholesterol and 2-dioleoyl-snglycero-3-phosphocholine (DOPC) served as blocks to stabilize the bilayer structure on the surface of nanoparticles. [32, 33] The PEGylation of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) prolonged the circulation time of nanoparticles in blood. [34] This lipid bilayer could self-assemble on the surface of nanoparticles via the interaction between dioleoyl phosphatidic acid (DOPA) and offer sufficient area to entrap MPLA, the TLR4 agonist with lipid-like structure.
Physical characteristics of nanoparticles, such as the size distribution, zeta potential and stability were described in our previous work. [31] The particle size of TLS-loaded ZnP NPs was ≈25-30 nm with regular morphology (Figure 2c-a) . After modified with lipid bilayer, morphology of TLS-loaded LZnP nanovaccine still remained a uniform size (Figure 2c-b The encapsulation efficiency of TLS into nanoparticles was measured by bicinchoninic acid (BCA) assay. We investigated the relation between the protein concentration and encapsulation efficiency. At the concentration of 1 and 2 mg mL −1 , the encapsulation efficacy of TLS in LZnPs NPs was 66.2 ± 2.7% and 50.8 ± 5.8%, respectively. In the higher protein concentration, encapsulation efficacy was slightly decreased while loading content of TLS was increased. Thus, we chose the concentration of TLS in 2 mg mL −1 in the following experiments.
Maturation of Dendritic Cells Induced by LZnP Nanovaccine In Vitro
The ability to promote DC maturation is a prior requirement of nanovaccine. The nanovaccine was evaluated in the efficiency to promote the maturation of DCs in vitro. Bone marrow derived dendritic cells (BMDCs) were harvested from mice and cultured in special media. On day 7, isolated cells were exposed to different formulations for 24 h. CD86, as a surface marker, was usually used as the identification of DC maturation. As shown in Figure 3a 
Effect of LZnP Nanovaccine on Immune Response In Vivo
We identified that LZnP nanovaccine had ability to prime DCs in vitro. To further explore the potential role of nanovaccine in immunization, C57BL/6 mice were used as animal models to study the performance of nanovaccine in vivo. Mice were divided into three groups and received TLS/LZnP+M, TLS+M, and saline, respectively. After immunization for three times, mice were sacrificed and LNs were harvested to obtain DCs. The isolated DCs were stained with anti-CD11c and anti-CD86 mAbs to evaluate the maturation of DCs. As shown in Figure 4a ,b, TLS-loaded LZnP nanovaccine significantly enhanced the expression of CD86, which was almost twice higher than the control group (p < 0.001). These data were consistent with the in vitro results demonstrated above. 
Proliferation and Activity of T Cells in Lymph Node
T lymphocytes play an important role in mediating the antitumor immune response. Naïve CD4 + T cells and CD8 + T cells recognize antigens and can be primed to differentiate into effector T cells. Activated CD4 + T cells produce cytokines . c-e) The production of TNF-α, IL-12, and IFN-γ after incubated with different formulations (n = 3). The differences between the control group and experimental groups were analyzed by using student's t-test (***p < 0.001, *p < 0.05). [35] Even there is a strict compartmentalization existed during the biogenesis of MHC class I and II, exogenous antigens still have opportunities to access MHC class I molecules. If exogenous antigens escape from endosomes into the cytoplasm, it will lead to crosspresentation. Exogenous antigens in the cytoplasm will enter into proteasomes and be cleaved into peptides, which can be loaded on the MHC class I molecules. [28] To further evaluate the efficiency of nanovaccine, we explored the activation of T cells in LNs. T cells in draining LNs were collected from primed mice and stained with anti-CD3, anti-CD4, anti-CD8 mAbs for flow cytometry analysis. The proliferation of CD3 + CD4 + T cells showed no significant difference (data not shown). And there was just a small discrepancy in proliferation of CD3 + CD8 + T cells between LZnP nanovaccine treated mice and that of other groups (Figure 5a ). Beyond our expectation, it seemed that the nanovaccine treatment failed to induce potent T cells response. However, when we turned to investigate the activity of T cells in LNs, the results showed a different tendency. As shown in Figure 5b , both CD3 + CD4 + T cells and CD3 + CD8 + T cells were significantly activated after immunization. The level of CD107 + expression on CD3 + CD8 + T cells induced by nanovaccine was about five times higher than the control. Thus we considered low level of T cells proliferation may be caused by the migration of T cells. It has been reported that activated T cells were endowed with the capacity to migrate from LN to target site through blood. [36] Besides, according to this result, we assumed that LZnP NPs may have the ability to enhance cross presentation. LZnP NPs have been identified with good stability in phosphate-buffered saline (PBS) (pH 7.4) even at day 4. However, when we changed the pH 7.4 PBS to pH 5.5 PBS, it became difficult for nanoparticles to maintain a stable structure. As shown in Figure S1 (Supporting Information), after 2 h, LZnP NPs maintained a uniform structure in pH 5.5 PBS and started to be degraded after 10 h. After being uptake by DCs, LZnP NPs entered into endosome and the environment around nanoparticles became acid, which may lead to degradation of nanoparticles and help the loaded antigens escape from endosome into the cytoplasm. This kind of acidic sensitive characteristic may be the reason that LZnP nanovaccine showed good activation of CD8 + T cells. Activity of T cells in LNs served as the evidence that the nanovaccine facilitated interaction between DCs and T cells and enhanced the antitumor activity of T cells.
Proliferation and Activity of T Cells in Spleen
Spleen, as an important immune organ, serves as another critical site for T cells activation. The proliferation of T cells in spleen was measured by flow cytometry. As shown in Figure 5c , the proportions of CD3 + CD4 + T cells and CD3 + CD8 + T cells were also elevated after treated with LZnP nanovaccine while TLS+MPLA basically did not promote the proliferation of T cells.
To verify that LZnP nanovaccine can induce specific killing activity on tumor, we used CTL assays to evaluate the efficacy of primed T cells. Immunized mice were sacrificed to obtain splenocytes as the effector cells. Then isolated effector cells c) The proliferation of CD3 + CD4 + and CD3 + CD8 + T cells in spleen (n = 3), and the difference between groups were analyzed by using one-way ANOVA analysis. (***p < 0.001, **p < 0.01 and *p < 0.05). d) The cytotoxicity of splenocytes from vaccination mice for tumor rejection (n = 6), and the differences between the control group and experimental groups were analyzed by using student's t-test. (***p < 0.001).
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were cultured with the target cells, B16F10, at the ratio of 5:1, 20:1, and 50:1, respectively. We measured the efficiency of primed T cells by calculating the proportion of activated tumor cells after specific lysis mediated by effector cells. As shown in Figure 5d , tumor-specific CTL activity was correlated with the ratio of effector:target (E:T) cells. It was shown that only sufficient quantity of effector cells could guarantee potent antitumor immune response. At the E:T ratio of 5:1, effector cells did not induce obvious lysis of tumor cells. It is true that one activated CTL is able to kill multiple target cells. However, when splenocytes were isolated and purified from spleen, it is difficult to guarantee that every obtained cell could be successfully activated. The existence of unprimed splenocytes may contribute to this phenomenon, which also happened in previous works. [37, 38] When the ratio was amplified ten times, the effector cells exhibited significant inhibition on target cells. For the splenocytes primed by LZnP nanovaccine, the lysis of tumor cells was up to 37.1%. CTLs undertake primary responsibility of killing tumor cells. LZnP nanovaccine was thus more effective in motivating T cells and inducing specific CTL response against tumor cells compared with free TLS with MPLA.
Evaluation of Nanovaccine and D PPA-1 in Therapeutic Protocol
In cancer treatment, even though vaccination can induce potent CTL response, how to tackle with resistance during development of the tumor also need to be addressed. During the activation of immune cells, negative feedbacks also participate and regulate balance of the immune system. For example, the interaction between PD-L1 and PD-1 can activate the suppressive mechanism on T cells. [4] In order to improve the antitumor efficiency of cancer immunotherapy, we expect to block the PD-1/PD-L1 pathway, providing more opportunities for T cells to fight against tumor. In the past decade, checkpoint antibodies with different targets molecules continuously came out. Targeting PD-1/PD-L1 pathway, antibodies can be categorized into two groups. One group is to block PD-L1 expressed on tumor cells and the other group is to interact with PD-1 expressed on T cells. In this work, a peptide-based immune checkpoint antagonist, D PPA-1, was employed as PD-L1 blockade to cooperate with LZnP nanovaccine. With the similar function of anti-PD-L1 antibody, D PPA-1 can bind with PD-L1 on the surface of tumor cells, thus blocking the PD-1/PD-L1 pathway.
To evaluate antitumor efficiency of nanovaccine, we first investigated the influence of vaccination frequency in B16F10 tumor model. After tumor challenging, mice were divided into four groups, which subcutaneously received saline, TLS+M (once a week for three times), TLS/LZnP+M (1 V, single injection) or TLS/LZnP+M (3 V, once a week for three times), respectively. Mice received nanovaccine only once showed better antitumor result than those treated with free antigens. However, it seemed not strong enough to maintain the antitumor immune response compared with three times vaccination ( Figure S2 , Supporting Information). Splenocytes and lymphocytes were isolated from tumor bearing mice to analyze the population of T cells. As shown in Figure S3 (Supporting Information), both groups treated with nanovaccine showed high population of CD3 + CD8 + T cells regardless of vaccination frequency in the regional LN. However, only after repeated vaccinations, the population of CD3 + CD8 + T cells in splenocytes could be upregulated. There was no significant upregulation of CD3 + CD4 + T cells population in both LN and spleen (data not shown). In the combination therapy based on LZnP nanovaccine and D PPA-1, mice were immunized on day 3 with therapeutic formulations for three times at the interval shown in Figure 6a . D PPA-1 (2 mg kg −1 ) was intraperitoneally injected once every day for 7 d after the occurrence of tumor according to the recommendation from Chang et al. [24] As shown in Figure 6b , vaccinations were capable to inhibit tumor growth, while the assistance from D PPA-1 achieved better therapeutic effect. Treatment based on LZnP nanovaccine and D PPA-1 significantly inhibited the development of tumor (p < 0.001). Even on day 21, the tumor growth was under effective control. The results also identified that D PPA-1 could serve as a potential candidate to collaborate with vaccination to induce potent antitumor immune response. On day 21, mice were sacrificed, tumor and other tissues were isolated for further investigation. The average tumor weight of TLS/LZnP+M + D PPA-1 was about eight times smaller than the control (Figure 6c ). The treatments that involved D PPA-1 also showed superiority over other groups (Figure 6c,d ).
In the hematoxylin and eosin (H&E) staining of isolated tumor, combination therapy effectively induced the lysis of tumor cells in deep area, which served as evidence to explain the excellent antitumor efficiency (Figure 6e ). The behavior of T cells was investigated to evaluate the synergistic effect of LZnP nanovaccine and immune checkpoint antagonist. The proliferation of CD3 + CD4 + T cells and CD3 + CD8 + T cells were elevated after treatment with TLS/LZnP+ M+ D PPA-1. In the CTL assay, splenocytes from mice received combination therapy induced the specific lysis of tumor cells up to 42.3% as shown in Figure 6f . This result showed good support to collaborate LZnP vaccine with D PPA-1 for cancer treatment. Immunization with TLSloaded LZnP nanovaccine motivated both CD4 + and CD8 + T cells. And D PPA-1 blocked the negative regulation of functional T cells. Owing to efficient activation of the immune system, the development of tumor was thus under a good control.
Combination of Nanovaccine and D PPA-1 in Prophylactic Protocol
We also evaluated the combination therapy in a prophylactic animal model. C57BL/6 mice were first divided into three groups and immunized with TLS/LZnP+M, TLS+M and saline, respectively. Three days after the final injection, immunized mice were inoculated with B16F10 cells. Mice with the occurrence of tumor were elected to carry on the immune checkpoint therapy. The inhibition of tumor growth indicated the feasibility of combination therapy based on LZnP nanovaccine and immune checkpoint therapy. LZnP nanovaccine inhibited tumor growth and exhibited relative superiority in deferring the occurrence of tumor with the help of D PPA-1 (Figure 7b) Figure 7c , mice treated with saline began to die on day 22 and no mice survived in the following two days. On day 26, the first mouse died in group of TLS/LZnP +M + D PPA-1, which had the tumor volume around 665.18 mm 3 on day 24. In the combination treatment group, the survival rate was extended to day 36, which was 12 d later than that of the control. Tumor volume of each mouse in every group was presented in Figure 6d . The H&E staining sections of sliced tumor in different treatment groups. f) The cytotoxicity of splenocytes from spleen in tumor bearing mice for tumor rejection (n = 4). The differences between the control group and experimental groups were analyzed by using student's t-test (***p < 0.001, **p < 0.01).
www.advancedsciencenews.com www.advhealthmat.de phase during the progress. The abnormal expansion of tumor was retarded after injection of D PPA-1. This may serve as the evidence that combination of D PPA-1 and nanovaccine is a favorable prophylactic protocol to hold back aggressive growth of tumor. However, no tumor-free mice were exhibited from the combination therapy. There is still a margin of improvement on the prevention and eradication of the aggressive B16F10 tumor. Recent studies showed that some alternative adjuvants achieved better synergistic antitumor effects with vaccination. [39, 40] In the next stage, different types of adjuvants should be investigated to collaborate with vaccine apart from MPLA. Moreover, the discovery of neoantigens provided potent tumor rejection antigens, [41] which maybe more suitable to be loaded into hybrid nanoparticles to compete immune evasion during the tumor development. Furthermore, D PPA-1 was employed as immune checkpoint antagonist to blockade PD-1/PD-L1 pathway because of the safety consideration, which could lead to a compromise between therapeutic effect and side effects. The antagonist may not be strong enough as an alternative to immune checkpoint antibody. Lastly, it showed in recent clinical research that the objective response rate of anti-PD-1 or anti-PD-L1 therapy was below expectation in some patients, [42, 43] which may be attributed to that the immune response in tumor microenvironment is really complex and dynamic. [44] Altogether, the nanovaccine may need to develop further combination with other therapeutic modality in the future.
Safety Evaluation of Combination Therapy Based on Nanovaccine and D PPA-1
To evaluate the safety of vaccine formulation and immune checkpoint therapy, heart, liver, spleen, lung, and kidney were harvested from treated mice and stained with H&E. As shown in Figure S4 PPA-1, respectively (n = 7). c) The survival rate of mice after treated with different groups (n = 7). d) The tumor growth of each mouse in prophylactic treatment (n = 7). The differences between the control group and experimental groups were analyzed by using student's t-test. (***p < 0.001). secreted AST and ALT in the normal range ( Figure S5 , Supporting Information). As to blood urea nitrogen (BUN), lactate dehydrogenase (LDH) and creatinine (CRE), which serve as an index to evaluate kidney function, the secretion level of each index in immunized mice had negligible difference compared with the control group.
Conclusion
In summary, we demonstrated the antitumor efficiency of LZnP nanovaccine and explored the feasible treatment modality by collaborating with immune checkpoint antagonist, D PPA-1, for the prominent inhibition of melanoma. TLS derived from B16F10 melanoma cells can provide adequate antigenic epitopes for T cells recognition. LZnP NPs have ability to protect TLS from external influences and promote the efficiency of antigen uptake and process. It indicated that LZnP nanovaccine can sufficiently induce the maturation of DCs and subsequently activate T cells both in vitro and in vivo. It has been reported that pre-infiltrated CD8 + T cells may exert positive effect on checkpoint blockade therapy. [45] The following immune checkpoint therapy may also benefit from the activation of T cells. D PPA-1 blockaded negative feedback motivated by immunotherapy, exhibiting the synergistic effect with vaccination. LZnP nanovaccine can induce potent antitumor effect and collaborate with D PPA-1 in both prophylactic and therapeutic treatments.
In this study, we demonstrated the possibility to apply vaccination of TLS-loaded LZnP NPs with immune checkpoint therapy of D PPA-1 peptide in melanoma models. This combination therapy based on nanovaccine and immune checkpoint therapy can sufficiently motivate the immune system and reasonably regulate the immune resistance conducted by tumor, serving as a promising treatment modality in the future cancer immunotherapy. In the following work, we will keep on optimization of the combination therapy.
Experimental Section
Materials and Reagents: DOPA, cholesterol, DOPC, DSPE-PEG2000, and MPLA were purchased from Avanti Polar Lipids, Inc. (Alabaster, USA). Cyclohexane was purchased from Aladdin. Igepal CO-520 and LPS were obtained from Sigma-Aldrich (St. Louis, MO). D-peptide antagonist D PPA-1 (NYSKPTDRQYHF) was synthesized by Bioyears (Wuhan Bioyeargene Biosciences Co. Ltd., China). Antimouse monoclonal antibodies (mAbs) against CD11c, CD86, CD3, CD4, CD8, and CD107 were purchased from BD Pharmingen.
Animals: Female C57BL/6 mice (6-8 weeks old) were purchased from the Hubei provincial center for disease control and prevention, China. All animal experiments were performed in the specific pathogen-free (SPF) condition. All experimental protocols were approved by the Ethics Committee of Huazhong University of Science and Technology, China.
Cells: B16F10 murine melanoma cell line was purchased from Chinese Academy of Sciences Cells Bank of China. B16F10 cells were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum, 100 U mL −1 penicillin G sodium and 100 µg mL −1 streptomycin sulfate. BMDCs were prepared as previously reported. [46] BMDCs were collected from marrow cavities of C57BL/6 mice and cultured in complete RPMI 1640 media supplemented with 10 ng mL −1 granulocyte/macrophage colony-stimulating factor (GM-CSF) and 5 ng mL −1 IL-4. Cells were maintained at 37 °C in 5% CO 2 humidified atmosphere.
Preparation of Tumor Lysate: TLS was prepared as previously reported. [46] First, B16F10 cells were suspended at 1 × 10 7 mL −1 cell density in 4 °C PBS. Then tumor cells were frozen in liquid nitrogen and thawed in 37 °C water bath. Following four times of freeze-thaw cycles, the suspension was centrifuged at high speed (10 000 g for 30 min) to remove cellular debris. Protein concentration of the supernatant was evaluated by BCA assay. Finally, the supernatant was subjected to freezedrying process for lyophilized TLS.
Preparation and Characterization of Vaccine Formulation: LZnP NPs were prepared as previously described. [31] 2 mg TLS was dissolved in 1 mL 500 × 10 −3 m Zn(NO 3 ) 2 . 100 µL of TLS contained Zn(NO 3 ) 2 was then dispersed in 4 mL cyclohexane/Igepal CO520 solution to form Zn phase. 100 µL of 100 × 10 −3 m Na 2 HPO 4 and 50 µL of 20 × 10 −3 m DOPA were dispersed in the same solution to form P phase. After stirring at room temperature for 30 min, the P phase was added into the Zn phase and kept stirring for 2 h. The ZnP NPs were collected by adding ethanol to disrupt the microemulsion and centrifuged at high speed (13 000 g for 15 min). The collected nanoparticles were further washed with ethanol for three times to remove surplus cyclohexane and surfactant and then store in 200 µL chloroform at 4 °C.
The collected ZnP NPs were further modified with lipids by adding cholesterol, DOPC and DSPE-PEG2000 at the molar ratio of 4:4:1 into ZnP NPs chloroform solution. After evaporating the chloroform, the lipids and ZnP NPs were incubated in PBS at 37 °C for 30 min. Then the TLS-loaded LZnP NPs were stored at 4 °C. The morphology of ZnP NPs in chloroform and LZnP NPs in PBS were detected by transmission electron microscopy (TEM, JEM-1230, Japan). The encapsulation efficiency of TLS was evaluated by BCA assay (Wuhan Bioyeargene Biosciences Co. Ltd., China). , 10 µg MPLA) once a week for three times. After 3 d of the final immunization, draining LNs and spleens from all groups were isolated for following analysis. LNs were grounded on strainer, then the collected cell suspension was centrifuged and washed in PBS to obtain lymphocytes. Splenocytes were processed in the similar method as LNs and the mouse lymphocyte isolating solution was applied for purification.
Maturation of BMDCs and Production of Cytokine In
To evaluate the maturation of DCs, cells isolated from draining LNs were stained with anti-CD11c and anti-CD86 mAbs, and analyzed by flow cytometry after 3 d of the final immunization. For the proliferation of T cells, cells from LNs and spleens were stained with anti-CD3, anti-CD4, anti-CD8 mAbs and analyzed by flow cytometry. Cells were also stained with CD107, anti-CD3, anti-CD4, and anti-CD8 mAbs to evaluate the activity of CTLs.
The antitumor effect of primed splenocytes was evaluated as previously reported. [31] B16F10 cells (2 × 10 3 cells per well) were seeded in 96-well plates. And purified lymphocytes served as effector cells against B16F10 cells at ratios of 5:1, 20:1, and 50: 1, respectively. After being incubated for 24 h, the viability of B16F10 cells was evaluated by using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) method.
To evaluate the secretion of cytokine IFN-γ, TNF-α, IL-12p70, peripheral blood was collected 3 d after the final immunization and analyzed by ELISA kit (eBioscience, USA).
Evaluation of Vaccine and D PPA-1 in Therapeutic Protocol: Mice were subcutaneously inoculated 5 × 10 4 B16F10 cells. On day 3 after tumor challenging, mice were divided into four groups, which received saline, TLS+M (once a week for 3 times) TLS/LZnP+M (3 V, once a week for three times) or TLS/LZnP+M (1 V, single injection), respectively. On day 19, mice were sacrificed for further analysis. Cells were harvested to evaluate the proliferation of CD3 + CD4 + and CD3 + CD8 + T cells in LNs. To evaluate the combination protocol in antitumor experiment, tumor-bearing mice were treated simultaneously with vaccine formulation and D PPA-1. The vaccination treatments were conducted on day 3, day 10, and day 17, and the immune checkpoint therapy based on D PPA-1 (2 mg kg −1 ) was started from day 9 and intraperitoneally injected once every day for a week. The tumor volume and body weight were measured every other day. On day 21, mice were sacrificed for further analysis. Cells were harvested to evaluate the proliferation of CD3 + CD4 + and CD3 + CD8 + T cells in LNs. The activity of primed splenocytes was carried out as the method mentioned above. Tumors and relative tissues (heart, liver, spleen, lung, and kidney) were harvested for H&E staining. Peripheral blood was collected to evaluate the levels of ALT, AST, BUN, LDH, and CRE respectively (Nanjing Jiangcheng Bioengineering Institute, China).
Combination of Vaccine and D PPA-1 in Prophylactic Protocol: In order to refine the combination immunotherapy, the antitumor effect in immunization protocol was further explored. C57BL/6 mice were first received vaccine formulation for three times. After 3 d of the last immunization, 5 × 10 4 B16F10 cells were subcutaneously inoculated in the right flank of each mouse. When incipient tumor was detected, D PPA-1 was intraperitoneally injected once every day for a week. The tumor diameter was measured every other day. Tumor volume was calculated by the formula 0.5 × length × width 2 .
Statistical Analysis: Data were presented as mean ± standard deviation (SD). The differences between the control group and experimental groups were analyzed by using student's t-test. The difference between groups were analyzed by using one-way ANOVA analysis followed by Tukey's posttest (GraphPad Software, La Jolla, CA). When the p value was less than 0.05, it was considered statistically significant.
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